title: Mifepristone followed by high-dose oxytocin drip for second-trimester abortion: a randomized, double-blind, placebo-controlled, pilot study.
abstract: OBJECTIVE
  To study the effect of mifepristone for priming and induction of second-trimester abortion in conjunction with a high-concentration oxytocin drip.
  
  
  METHODS
  Prospective, randomized, placebo-controlled, pilot study. Thirty patients with 14-25 weeks' gestational age abortion received either 600 mg of mifepristone or placebo in 3 identical capsules followed, 48 hours later, by a high-concentration oxytocin drip (HCOD).
  
  
  RESULTS
  The mifepristone group showed significantly higher success rates as compared to the placebo group (92.3% vs. 52.9%, p<0.05). The time interval to abortion (from beginning of HCOD) was also significantly shorter in the mifepristone group as compared to the placebo group (11.3 +/- 6.0 hours vs. 17.6 +/- 6.5 hours, p <0.05). Probability of success as calculated by the Kaplan-Meier method was found to be highly significant (log rank test p = 0.001).
  
  
  CONCLUSIONS
  Our results suggest that mifepristone is very effective for priming and induction of second-trimester abortion and shortens significantly the time interval to evacuation following HCOD.
authors.affiliation: Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Ein-Kerem, POB 12000, Jerusalem 91120m Israel. assaf.benmeir@gmail.com
authors.forename: Assaf
authors.initials: A
authors.lastname: Ben-Meir
authors.forename: Yair
authors.initials: Y
authors.lastname: Erez
authors.forename: Tomer
authors.initials: T
authors.lastname: Feigenberg
authors.forename: Yaron
authors.initials: Y
authors.lastname: Hamani
authors.forename: Neri
authors.initials: N
authors.lastname: Laufer
authors.forename: Nathan
authors.initials: N
authors.lastname: Rojansky
mesh_terms: D000019:Abortifacient Agents / Q000008:administration & dosage*; D000028:Abortion, Induced; D000030:Abortion, Missed / Q000628:therapy; D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D015735:Mifepristone / Q000008:administration & dosage*; D010121:Oxytocin / Q000008:administration & dosage*; D010865:Pilot Projects; D010919:Placebos; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D055815:Young Adult
chemical_list: D000019:Abortifacient Agents; D010919:Placebos; D015735:Mifepristone; D010121:Oxytocin